Wednesday, 26 April 2017


Highway developer Dilip Buildcon has bagged three road projects worth Rs 3,269 crore in Maharashtra from the National Highway Authority of India.

Three separate SPVs (special purpose vehicles/entities) have been incorporated into the projects, said an official statement released by the company on Wednesday, 26 April 2017.

"The company has informed about the receipt of Letter of Award from the National Highways Authority of India, Ministry of Road Transport and Highways, for three projects in a single stretch in the state of Maharashtra," Dilip Buildcon Ltd (DBL) said in a BSE filing.

It further said: "DBL has incorporated three SPV companies for three projects valued at Rs 3,269 crore in Maharashtra." 

Earlier on Monday, the Airport Authority of India has declared Dilip Buildcon Limited, Bhopal as Lowest -1 (L-1) bidder for Construction of Parallel Taxi Track and associated civil & electrical works at Dabolim Airport, Goa.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

One of the leading Indian academic content producing company, S Chand and Company Limited’s IPO issue is open for subscription. On the first day of subscription, as per the data available with the NSE as of 1400 hours, the issue attracted total bids of 12,61,810 and total bids received at cut-off price stands at 7,75,368. The total issue size stands at 76,85,284 shares.

The IPO issue as of 2 pm on Wednesday was subscribed by 16%. On April 25, the company raised nearly Rs 219 Cr from anchor investors.

The price band is fixed at Rs 660 per share to Rs 670 per share with face value of each share pegged at Rs 5 per share. The IPO issue opens on April 26, 2017, and closes on April 28, 2017. The company is going to raise funds through fresh issue of equity shares, aggregating up to Rs 3250 million. The company is also raising funds through offer for sale of 60,23,236 equity shares. The face value of equity shares is pegged at Rs 5 per share.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

PVR Limited has signed a deal with IMAX for additional 5 screens, said Ajay Bijli, CEO, PVR Limited, while speaking to a leading business channel, on Wednesday.
 
The installation of the additional screens would cost around Rs 55 crore, said Bijli.
 
IMAX is known for delivering better movie experience.
 
The CEO of PVR, in his interview also said that Q3 got impacted due to demonetisation.
 
IMAX previously had wished to add screens and was in talks with the top cinema operators of the country for the same.
 
Multiplexes around the country are expected to witness a good run as the mega release of Bahubali-2 is on the cards.


For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Tuesday, 25 April 2017


April 25, 2017, is the last day of trading in the Cairn India Limited stock. From Wednesday onwards, investors cannot trade in the Cairn India Limited share and its derivatives contracts.

The debt-ridden Vedanta Limited, the parent company has acquired Cairn India Limited. As per the merger deal, the shareholders of Cairn India Limited will get one equity share of Vedanta; and four redeemable preference shares of face value Rs 10 and coupon rate of 7.5%.

The record date for the swap of shares is set at April 27, 2017.

Additional to the extra stocks of Vedanta Limited, the shareholders of Cairn India Limited would get the interim dividend of Rs 17.7 per equity share.

On the last day of trading, Cairn India Limited is losing its sheen, and is trading lower by around 0.6% at Rs 281.15 per share.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) cleared the company’s Investigational New Drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to XOLAIR® (omalizumab) in healthy adult volunteers between 18 – 65 years of age.

“This marks the second IND activation in 2017 for our growing respiratory portfolio,” said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals.

“In the seven years since the U.S. approval process for biosimilar medicines was signed into law, there have been few candidates successfully developed. GBR 310 has the potential to be among the first biosimilar candidates to be submitted for approval for a respiratory or allergic disease.” GBR 310 is a recombinant DNA-derived humanized immunoglobulin G1 kappa monoclonal antibody.

Its current proposed indication is for the treatment of allergic asthma and chronic idiopathic urticaria. The reference product for GBR 310 is omalizumab, available under the brand name XOLAIR. According to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 Billion in the U.S. 1

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Ballarpur Industries (BILT), a Gautam Thapar-controlled company for selling its Malaysian forest arm, Sabah Forest Industries, is reportedly is in talks with a Chinese giant, Nine Dragons.

According to a report tabled by a leading business news portal, the deal will be for around $350 million. This will be a yet another effort to deleverage the BILT balance sheet.

BILT for some time is in talks with Nine dragons and the discussion is likely to lead to a binding agreement soon, as per the news report. BILT is one India’s largest manufacturer of writing and printing paper.

In a first significant overseas acquisition by an Indian paper company, BILT had acquired Sabah for almost $261 million. The latter company also makes paper-related products and offers wood-related products such as rough and chemically treated sawn timber and panel-based products which include, raw plywood and dried veneer, said the news report. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Monday, 24 April 2017


Stocks of Bharat Financial Inclusion, a non-banking financial company/micro finance institution, on Monday, witnessed a sharp jump by 4.2% on the NSE.

The stock hit an intraday high of Rs 780.10 per share, and an intraday low of Rs 747.70 per share on the BSE. The stock on July 29, 2016, hit its 52-week high of Rs 939 per share; and on December 27, 2016, it hit its 52-week low of Rs 465 per share.

The stock delivered over 32% returns in a period of one year, outperforming the BSE Mid-cap and Nifty Financial Services indices’ over the same time span.

The Company is engaged in providing micro finance services to women in the rural areas of India, enrolled as members and organised as Joint Liability Groups.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717